Neil Clark speaks to Endpoint – ‘UK biotech hands off mid-stage C. difficile drug in up to $570M deal’
Thursday March 16, 2023
Thursday March 16, 2023
Destiny Pharma’s CEO, Neil Clark, speaks to Endpoint. For the full article ‘UK biotech hands off mid-stage C. difficile drug in up to $570M deal’, please click here